Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.

Join global expert Dr. Eric Bateman as he discusses how exacerbations in patients with COPD are different than exacerbations in patients with asthma.
Dr Tzivinikos discusses the importance of early identification and management of pediatric EoE to improve long-term outcomes
Learn from Prof. Papadopoulou as she highlights challenges in identifying EoE in pediatric patients and the consequences of delayed diagnosis.
Profs. Greuter, Savarino, and Giordano discuss multidimensional EoE assessment, tailoring long-term care to patient needs, and recent clinical data.
Join Dr. Aceves and Ms. Ugras as they share their insights on how to identify potential patients with EoE and the importance of early diagnosis.

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in patients with asthma.
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP
Prof. Salvatore Oliva discusses the latest clinical data for EoE that included patients from childhood to adulthood.
Learn how a food bolus impaction event can help identify a patient with EoE and the importance of multiple disease domains in assessing EoE.
Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.